Breaking News, Collaborations & Alliances

Seattle Genetics Expands AbbVie ADC Pact

AbbVie gains additional rights to Seattle Genetics technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Seattle Genetics has expanded its antibody-drug conjugate (ADC) collaboration with AbbVie, under which AbbVie will pay $25 million upfront for additional rights to use Seattle Genetics’ ADC technology against AbbVie oncology targets, including Seattle Genetics’ pyrrolobenzodiazepine (PBD) dimer ADC technology and EC-mAb site-specific conjugation technology. Seattle Genetics is eligible to receive as much as $255 million in potential license fees and development and commercial milestones per targ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters